Jing‐Houng Wang

Kaohsiung Medical University — Taiwan

Medicine · Health Sciences

22h-index1.6kcitations62works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver Disease Diagnosis and Treatment(41), Hepatitis C virus research(29), Hepatitis B Virus Studies(25), Hepatocellular Carcinoma Treatment and Prognosis(20), Liver Disease and Transplantation(16)

Publications59 total

Prognostic Nutritional Index Predicts Outcomes in Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab: A Propensity Score-matched Analysis
Journal of Clinical and Translational Hepatology·2025Open Access
Proton Beam Therapy Boosts Outcomes of Atezolizumab/Bevacizumab in Advanced Hepatocellular Carcinoma: A Propensity Score Analysis
Liver International·2025· 1 citedOpen Access
Changing epidemiology of hepatitis C virus infection and liver disease mortality in Taiwan
Journal of the Formosan Medical Association·2025· 1 citedOpen Access
Usefulness of Gamma‐Glutamyl Transferase and Sequential Carbohydrate‐Deficient Transferrin for Unhealthy Alcohol Use Screening in Indigenous Communities
The Kaohsiung Journal of Medical Sciences·2025Open Access
Significant Decline in <scp>HCV</scp> ‐Related Mortality From Liver Cirrhosis and Chronic Liver Disease (2015–2022): A Sentinel Center Study
Liver International·2025· 3 citedOpen Access
Impact of Add‐On Hepatobiliary Abbreviated Magnetic Resonance Imaging on Ultrasound Hepatoma Surveillance for Liver Cirrhosis‐ a Randomized Study
The Kaohsiung Journal of Medical Sciences·2025Open Access
Survival outcome with liver resection versus percutaneous radiofrequency ablation in patients with 2–3 cm single hepatocellular carcinoma
Asian Journal of Surgery·2025· 1 citedOpen Access
Dynamic Muscle Atrophy Predicts Outcomes in Patients with Unresectable Hepatocellular Carcinoma Treated with First-Line Lenvatinib: A Retrospective Study in Taiwan
Gut and Liver·2025Open Access
Long-term risk of depression and the impact of risk factors among chronic hepatitis C patients after successful antiviral therapy: A nationwide real-world Taiwanese cohort (T-COACH)
Journal of the Formosan Medical Association·2025Open Access
Overall survival was inferior in octogenarians with early-stage hepatocellular carcinoma undergoing percutaneous radiofrequency ablation
The American Journal of the Medical Sciences·2025· 1 cited
Comparing Health Insurance-ReimbursedFirst Line Lenvatinib and Self-paid Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma
2024Open Access
Comparison of serum <scp>WFA</scp><sup>+</sup>‐<scp>M2BP</scp>, <scp>FIB</scp>‐4, and <scp>APRI</scp> for cirrhosis and esophageal varices prediction in hepatoma patients
Advances in digestive medicine·2024Open Access
Psoas muscle area as a predictor of low muscle mass in Asian patients with compensated advanced chronic liver disease
Clinics and Research in Hepatology and Gastroenterology·2024· 5 citedOpen Access
Conditional survival after radiofrequency ablation for early-stage hepatocellular carcinoma
2024Open Access
Overall survival was inferior in octogenarians with early-stage hepatocellular carcinoma undergoing percutaneous radiofrequency ablation. 
2024Open Access
Impact of Genomic Alterations on the Clinical Outcome of Patients With Hepatitis B-related Hepatocellular Carcinoma Receiving Curative Surgery: A Retrospective Cohort Study
Anticancer Research·2023· 2 citedOpen Access
Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
BMC Cancer·2023· 15 citedOpen Access
Regional Differences in Clinical Presentation and Prognosis of Patients With Post–Sustained Virologic Response Hepatocellular Carcinoma
Clinical Gastroenterology and Hepatology·2023· 8 citedOpen Access
Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation
Cancers·2023· 13 citedOpen Access
Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B
Alimentary Pharmacology & Therapeutics·2023· 8 cited
page 1 of 3Next →

Frequent Co-authors

Sheng‐Nan Lu(31), Tsung‐Hui Hu(25), Chao‐Hung Hung(20), Chien‐Hung Chen(18), Yi‐Hao Yen(15), Chuan‐Mo Lee(13), Chien‐Hung Chen(12), Sheng‐Nan Lu(12), Chao‐Hung Hung(11), Kwong‐Ming Kee(11), Chao‐Hung Hung(9), Chi‐Sin Changchien(9), Yuan‐Hung Kuo(9), Po‐Lin Tseng(8), Cheng‐Yuan Peng(6), Kuo‐Chin Chang(6), Chien‐Fu Hung(5), Chih‐Chi Wang(5), Hsueh‐Chou Lai(5), Chien‐Wei Su(4)